Benzinga

Benzinga

Benzinga

sabato, settembre 05

GeneDx Holdings Corp

WGSNASDAQ
Trade with Public
Trade with Public
$85.99
-1.40-1.6%
In chiusura: Sep 4, 5:00 PM EST
$84.00
-1.99-2.31%
Post-mercato: 6:05 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoConfrontaOpzioniRapporto azionario

GeneDx Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for GeneDx Holdings (WGS).

Price Target Range — 11 Quarters

Analyst Consensus — 10 Analysts

9Buy
1Hold
Consensus RatingBuy# Analysts10Avg. Consensus PT$88Upside to Avg. PT+4.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 4, 2026Canaccord GenuityKyle MiksonPT RaiseBuy$75→$90
Aug 4, 2026BTIGMark MassaroMaintainedBuy$90
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Raises Price Target to $90

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $75 to $90.
Benzinga Newsdesk

PRO
BTIG Reiterates Buy on GeneDx Holdings, Maintains $90 Price Target

BTIG analyst Mark Massaro reiterates GeneDx Holdings (NASDAQ:WGS) with a Buy and maintains $90 price target.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on GeneDx Holdings, Raises Price Target to $74

Guggenheim analyst Subbu Nambi maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and raises the price target from $70 to $74.
Benzinga Newsdesk

PRO
Piper Sandler Maintains Overweight on GeneDx Holdings, Raises Price Target to $63

Piper Sandler analyst David Westenberg maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and raises the price target from $50 to $63.
Benzinga Newsdesk

PRO
Canaccord Genuity Maintains Buy on GeneDx Holdings, Lowers Price Target to $75

Canaccord Genuity analyst Kyle Mikson maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $100 to $75.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Overweight on GeneDx Holdings, Lowers Price Target to $75

Wells Fargo analyst Brandon Couillard maintains GeneDx Holdings (NASDAQ:WGS) with a Overweight and lowers the price target from $155 to $75.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved